Drug
BDB001 clinical trials
Also written EIK1001.
- studies test it
- 12
- open now
- 3
- in phase 3
- 4
- first study started
- 2019
Keep track of what changes. Save the BDB001 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
12 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 3 |
| 2022 | 1 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 7
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 0
Staidson (Beijing) Biopharmaceuticals Co., Ltd (8) · Eikon Therapeutics (4)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses BDB001 is read from its arms, and is right about nine times in ten.
Testing it · 12
- A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.RecruitingPhase 2/3Eikon TherapeuticsNCT07365319Written as EIK1001
- Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.RecruitingPhase 2/3Eikon TherapeuticsNCT06697301Written as EIK1001
- BDB-001 Phase III Trial in ANCA-Associated VasculitisRecruitingPhase 3Staidson (Beijing) Biopharmaceuticals Co., LtdNCT07168161Written as BDB-001 injection
- BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid TumorsCompletedPhase 2Eikon TherapeuticsNCT04819373Written as BDB001
- BDB001-102: Open Label Dose Escalation of BDB001 in Combination w AtezolizumabCompletedPhase 1Eikon TherapeuticsNCT04196530Written as BDB001 (EIK1001)
- Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated VasculitisCompletedPhase 1/2Staidson (Beijing) Biopharmaceuticals Co., LtdNCT05197842Written as BDB-001 injection
- Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDSTerminatedPhase 2/3Staidson (Beijing) Biopharmaceuticals Co., LtdNCT04449588Written as BDB-001 Injection
- A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 PatientsTerminatedPhase 1Staidson (Beijing) Biopharmaceuticals Co., LtdNCT05075304Written as BDB-001 injection
- Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)CompletedPhase 1/2Staidson (Beijing) Biopharmaceuticals Co., LtdNCT05103423Written as BDB-001 Injection
- Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)CompletedPhase 2Staidson (Beijing) Biopharmaceuticals Co., LtdNCT05093855Written as BDB-001 Injection
- Safety and Tolerability of BDB-001 Injection in Healthy SubjectsCompletedPhase 1Staidson (Beijing) Biopharmaceuticals Co., LtdNCT05360927Written as BDB-001 injection
- Tolerability and Safety of BDB-001 Injection in Healthy SubjectsCompletedPhase 1Staidson (Beijing) Biopharmaceuticals Co., LtdNCT05361005Written as BDB-001 injection
Given in every arm · 2 — BDB001 is usual care beside what is tested
- A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLCActive, not recruitingPhase 2Eikon TherapeuticsNCT06246110Written as EIK1001
- BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With PembrolizumabCompletedPhase 1Eikon TherapeuticsNCT03486301Written as BDB001 (EIK1001)
Codes
What other systems call BDB001 · ClinicalTrials.gg INT001726
- MeSH (NLM) C000719787BDB001One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000719787 | BDB001 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.